|
Canada-0-IMPRINTING företaget Kataloger
|
Företag Nyheter:
- Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
- Bempedoic Acid Reduces Major Adverse Cardiovascular Events . . .
Tip for Patients: For patients who cannot take a statin, bempedoic acid (Nexletol) is an alternative to statin therapy for prevention of cardiovascular disease in high-risk patients without significant liver or kidney disease
- Nexletol shows CLEAR benefit in cardiovascular outcome trial
New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- NEXLIZET® NEXLETOL® CLEAR Outcomes Trial Information
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
- Statin alternative lowers heart-related deaths - Harvard Health
The cholesterol-lowering drug bempedoic acid (Nexletol) can be a good alternative for people who can't take statins A 2023 study found that compared with a placebo, bempedoic acid can lower the risk of heart attacks and related problems
- LABEL - accessdata. fda. gov
In the cardiovascular outcomes trial, in which 7,001 patients were exposed to NEXLETOL and 6,964 patients were exposed to placebo for a median of 3 1 years [see Clinical Studies, (14 1)], adverse reactions led to discontinuation of treatment in 11% of NEXLETOL-treated patients and 10% of placebo-treated patients
- In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
CONCLUSION ― In one large clinical trial in statinintolerant patients who had or were at high-risk for cardiovascular disease, the oral adenosine triphosphate- citrate lyase (ACL) inhibitor bempedoic acid (Nexletol) modestly reduced the risk of a 4-component composite of major adverse cardiovascular events (MACE) compared to placebo
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
- CLEAR Outcomes: Bempedoic Acid Reduces Cardiovascular Events . . .
The non-statin lipid-lowering medication bempedoic acid (Nexletol®) has demonstrated a significant reduction in the risk of cardiovascular events in a large outcomes study of statin-intolerant patients treated for primary or secondary cardiovascular prevention
|
|